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Abstract
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can
also occur in a regulated manner. Necroptosis, a type of programmed necrosis is defined as a death receptor-initiated
process under caspase-compromised conditions. The process requires the kinase activity of receptor-interacting protein
kinase 1 and 3 (RIPK1 and RIPK3) and mixed lineage kinase domain-like protein (MLKL), as a substrate of RIPK3. The further
downstream events remain elusive. We applied known inhibitors to characterize the contributing enzymes in necroptosis
and their effect on cell viability and different cellular functions were detected mainly by flow cytometry. Here we report that
staurosporine, the classical inducer of intrinsic apoptotic pathway can induce necroptosis under caspase-compromised
conditions in U937 cell line. This process could be hampered at least partially by the RIPK1 inhibitor necrotstin-1 and by the
heat shock protein 90 kDa inhibitor geldanamycin. Moreover both the staurosporine-triggered and the classical death
ligand-induced necroptotic pathway can be effectively arrested by a lysosomal enzyme inhibitor CA-074-OMe and the
recently discovered MLKL inhibitor necrosulfonamide. We also confirmed that the enzymatic role of poly(ADP-
ribose)polymerase (PARP) is dispensable in necroptosis but it contributes to membrane disruption in secondary necrosis.
In conclusion, we identified a novel way of necroptosis induction that can facilitate our understanding of the molecular
mechanisms of necroptosis. Our results shed light on alternative application of staurosporine, as a possible anticancer
therapeutic agent. Furthermore, we showed that the CA-074-OMe has a target in the signaling pathway leading to
necroptosis. Finally, we could differentiate necroptotic and secondary necrotic processes based on participation of PARP
enzyme.
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Introduction
Necrosis is considered as a direct cause or as a simultaneously
occurring secondary phenomenon of cell death. Necrosis is
important in many human diseases such as neurodegenerative
diseases [1], pancreatitis [2], trauma [3], ischemia reperfusion in
heart attack [4] or in brain injury [5]. Nevertheless, accumulating
evidences have confirmed that necrotic cell death can also be a
regulated event and therefore be classified as programmed cell
death in line with apoptosis [6–11]. A novel, necrotic-like, caspase-
independent cell death form has been recently described and
termed as necroptosis [12]. Degterev et al. demonstrated that
stimulation of the extrinsic apoptotic pathway by tumor necrosis
factor-alpha (TNFa) or Fas ligand (FasL) under caspase-compro-
mised conditions in certain cell types resulted in a necrotic-like
process [12]. This pathway can be hampered by a small molecular
weight inhibitor called necrostatin-1 (Nec), which acts by
inhibiting the kinase activity of receptor-interacting protein kinase
1 (RIPK1) [13] and by necrosulfonamide (NSA), an inhibitor of
mixed lineage kinase domain-like protein (MLKL), substrate of
receptor-interacting protein kinase 3 (RIPK3) [14].
The most widely studied pathway leading to necroptosis is
triggered by TNFa (see reviews [15,16]) which is a classical
inducer of the extrinsic apoptotic pathway. Tumor necrosis factor
receptor 1 (TNF-R1) upon activation by TNFa undergoes rapid
conformational changes. Rearrangement of the intracellular part
of TNF-R1 provides docking surface for TNFa receptor-associ-
ated death domain protein (TRADD) and several different
ubiquitin ligases to form the so-called membrane-associated
complex I [17]. Polyubiquitination of RIPK1 in complex I
contributes to the release of nuclear factor kappa-B (NFkB) and
the activation of the pro-survival pathway [8,18]. If the pro-death
signal is stronger or lasts longer than the pro-survival signal, the
internalized TNF-R1 and the deubiquitinated RIPK1 form a new
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41945cytoplasmic complex. In the cytosolic complex II the activated
caspase-8 directs cell to apoptosis and with the cleavage of RIPK1
and RIPK3 prevents the fulfillment of necroptosis. Under caspase-
deficient conditions cleavage of RIPK1 and RIPK3 is postponed
and, as a consequence, kinase activities of RIPK1 and RIPK3
remain active. Necrosome is formed due to the phosphorylation-
driven assembly of RIPK1 and RIPK3 containing complex IIB
[17,19], that subsequently leads to necroptosis [20,21]. The
further downstream events of necroptosis are rather enigmatic (see
review [8]). Nowadays, extensive research focuses on the
molecular background of necroptosis [22–25] and on the
identification of necroptosis in physiological [26,27] or patholog-
ical [28,29] conditions. Recently Tenev et al. have shown the
receptor- and complex I-independent assembly of Ripoptosome in
response to genotoxic stress [25]. Moreover Feoktistova et al.
confirmed that loss of cIAPs can promote the spontaneous
formation of an intracellular platform which is able to activate
both apoptosis and necroptosis [23]. For further details see review
[24]. Most recently MLKL was identified as the target of RIPK3
[14]. MLKL is phosphorylated by RIPK3 and this step seems to
be critical for the fulfillment of necroptosis.
Previously we studied the nature of the switch mechanism
between apoptosis and necrosis and investigated the intrinsic
apoptotic pathway in staurosporine (STS)-treated U937 cells [30].
Figure 1. TRAIL induces necroptosis in the presence of caspase inhibitor. TRAIL-induced cell death in U937 cells. Cells were treated as
indicated for 20 hrs. (A) Cytospins were stained with hematoxylin-eosin. Blue arrows show the apoptotic, green ones the necrotic cells (400x)
(representative of n=2). Scale bar on the first subfigure applies to all the figures in the panel. (B) Western blot analysis of fragmented PARP-1 protein.
Full length PARP-1 is 116 kDa, cleaved PARP-1 fragment is 89 kDa (representative of n=2). (C) TRAIL-induced caspase activity in U937 cells. U937 cells
were exposed to 50 ng/mL hr-TRAIL (114–281 aa) in the presence or absence of zVD (5 mM) for the indicated period of time. The ordinate shows the
slope of the measured DEVDase activity curves of a representative experiment carried out in triplicates. (D) FACS analysis of treated cells. Plasma
membrane integrity was analyzed after PI staining of cells. Inserted values on histograms show the percentage of the marked population
(representative of n=7). (E-F) Nec and GA protected U937 cells from TRAIL+zVD-induced necroptosis. U937 cell were exposed to TRAIL (50 ng/mL) in
the presence or absence of zVD (5 mM) and (E) Nec (10 mM) or (F) GA (1 mM) for 20 hrs. PI stained cells were analyzed for membrane permeability.
Percentages of PI positive cells were determined (n=7 for Nec and n=4 for GA). Values are mean6SD. *, P,0.05, **, P,0.01 and ***, P,0.001
calculated by Student’s t-probe.
doi:10.1371/journal.pone.0041945.g001
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and it is a wide spectrum inhibitor of protein kinases [31]. STS
initiates apoptosis by enhancing mitochondrial permeability
transition [32,33]. In absence of clearing mechanism, apoptotic
cell death process is followed by secondary necrosis, disruption of
the plasma membrane. Earlier, we [30,34] and others [35] found
that STS could provoke necrosis in caspase-compromised cancer
cells. We were interested to examine the role of necroptosis in the
same necrotic process, in spite of the fact that necroptosis is
generally defined as a result of a death receptor-triggered cell
death pathway [12].
In this report we aimed to characterize the STS-induced
necrosis in U937 cell line. We were curious about the role of
RIPK1, poly(ADP-ribose)polymerase (PARP) and the effect of
lysosomal enzyme inhibitor CA-074-OMe in STS-triggered
necrosis to differentiate secondary necrosis and necroptosis [34].
We also focused on the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL)-induced necroptotic type of cell death
that might has high clinical relevance because of the known ability
of TRAIL cytokine to induce apoptosis in a variety of human
cancer cell lines while leaving most of normal cells unaffected [36].
We concluded that both TRAIL and STS can induce at least
partially necroptosis which can be completely hampered by CA-
074-OMe but not by the PARP inhibitor PJ-34.
Results
TRAIL Induces Necroptosis in U937 Cell Line in the
Presence of a Caspase Inhibitor
To build a reliable model system, first, we tested the classical
death ligand-induced necroptosis with TRAIL cytokine. TRAIL is
known to induce apoptosis in a wide variety of tumor cells [37,38]
and necroptosis in Jurkat cells [39]. We selected U937 monocytic
cell line which was shown to undergo necroptosis induced by
TNFa in the presence of a caspase inhibitor [12].
We found U937 cells sensitive to TRAIL cytokine treatment.
Light microscopic studies of hematoxylin-eosin stained samples
confirmed that TRAIL treatment generated apoptotic nuclear
DNA condensation (Fig. 1A) together with nucleosomal DNA
fragmentation revealed by flow cytometric sub-G1 assay method
(Fig. S1). These changes resulted in apoptotic PARP-1 fragmen-
tation (Fig. 1B) due to caspase-3 activation (Fig. 1C). Finally, signs
of secondary necrosis occured when cells turn permeable for
propidium iodide (PI) (Fig. 1D, 1E).
When cells were pre-treated with the pan-caspase inhibitor z-
VD.fmk (zVD) one hour before TRAIL treatment, the executioner
caspase activation was prevented (Fig. 1C), therefore PARP-1
processing was inhibited (Fig. 1B). Apoptotic type oligonucleoso-
mal DNA fragmentation diminished, however, the high molecular
weight fragmentation of DNA appeared resembling necrosis
[40,41] (Fig. S1) and DNA condensation was evaded (Fig. 1A).
Instead of apoptotic morphology, dying cells were swelling and
showing a ‘‘ghost-like’’ morphology resembling necrosis (Fig. 1A).
Plasma membrane rupture detected and quantified by PI uptake
revealed that the number of PI positive cells in caspase inhibitor-
sensitized U937 cells upon TRAIL treatment were increasing
compared to cells treated with TRAIL alone (Fig. 1D, 1E). In the
presence of RIPK1 inhibitor Nec (10 mM), PI uptake was reduced
only marginally in caspase-competent (secondary necrotic) cells,
while it was completely reduced in caspase-compromised cells after
TRAIL treatment (Fig. 1D, 1E).
To further confirm the role of RIPK1 activity in TRAIL-
induced necroptotic or secondary necrotic cell death processes we
studied the effect of geldanamycin (GA, 1 mM). GA, an inhibitor of
the heat shock protein 90 kDa (HSP90) [42], was known to
downregulate the protein level of RIPK1 [43] and therefore was
expected to halt necroptosis. Indeed, GA pre-treatment (4 hrs)
significantly reduced the extent of TRAIL-induced necroptosis
detected by PI uptake (Fig. 1F). At the same time GA enhanced
the extent of TRAIL-induced apoptosis (Fig. S1), possibly via
downregulating the NFkB signaling pathway [44]. Furthermore
GA caused cell cycle inhibition in G2 phase (Fig. S1). Secondary
necrosis (Fig. 1F) was also increased in line with the elevation of
DNA fragmentation (Fig. S1).
These results indicate that in the presence of caspase inhibitor,
TRAIL-exposed U937 cells undergo necroptosis instead of
apoptosis, moreover TRAIL-triggered necroptosis can be sus-
pended both by Nec and GA.
STS Induces Primary Necrosis in the Presence of a
Caspase Inhibitor
To study the STS-evoked necrosis we tested the effect of the
RIPK1 inhibitor under caspase-compromised conditions. Nec
concentration dependently abrogated the necrosis confirmed by
the reduced ratio of PI positive cells (Fig. S2A). At the applied
concentration Nec (10 mM) and GA (1 mM) arrested the necrosis
after 12 hrs of incubation time confirmed by flow cytometry and
by fluorescent microscopic studies using Hoechst dye and PI
double staining technique (Fig. 2A, 2B, 2C). After prolonged
(20 hrs) treatment the STS and zVD-triggered plasma membrane
rupture was diminished only partially by Nec (Fig. 2D, 2E, 2F) or
GA (Fig. 2G). Furthermore, Nec unaffected the caspase-mediated
DNA fragmentation and condensation either after shorter (8 hrs)
(Fig. S2B, S2C) or after longer incubation time (20 hrs) (Fig. S2D,
S2E). GA affected only moderately the DNA fragmentation (Fig.
S2F) delaying the appearance of the shorter nucleosomal
fragments (Fig. S2H). The STS-induced secondary necrosis, the
final stage of cell death, was unaffected by either Nec (Fig. 2E) or
GA (Fig. 2G).
Concerning the apoptotic parameters, zVD prevented the
executioner caspase activation (Fig. S2G). It is worth to mention
that the proportion of sub-G1 cells was reduced both by Nec (Fig.
S2E) and by GA (Fig. S2F) after prolonged STS treatment in the
presence of zVD. However this observed reduction correlated well
with the reduced ratio of the number of PI positive cells (Fig. 2E,
2G). This correlation denotes that the number of sub-G1 DNA
containing cells observed when STS and the caspase inhibitor
were applied, is unequal with the classical fragmented DNA
containing population obtained after STS treatment alone. STS
and zVD-exposed samples showed high molecular weight DNA
fragments confirmed by agarose gel electrophoresis, accompanied
with low molecular weight DNA fragments that are primarily
smear-like, opposite to apoptotic DNA fragmentation and typical
to necrosis [40,41]. STS treatment resulted in nucleosomal DNA
ladder fragmentation trimmed by postmortem DNase activity.
(Fig. S2H).
These results indicate that STS-induced apoptosis in U937 cells
ensued by secondary necrosis, while under caspase-compromised
conditions STS induced primary necrosis that is partially
inhibitable by Nec and GA, two drugs affecting RIPK1 activity.
STS and TRAIL Induce RIPK1 and MLKL-dependent
Necroptosis
To confirm the role of RIPK1 in the STS-induced necroptosis,
we tested the proteolytic degradation of RIPK1 in U937 cell line
by Western blot analysis. STS-triggered caspase activation led to
RIPK1 processing (Fig. 3A). Full length RIPK1 (,75 kDa) was
Staurosporine Can Induce Necroptosis
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[45]. The cleavage at the carboxyl group of aspartic acid residue
(at amino acid position of 324) resulted in two fragments, a shorter
N-terminal part which contains the kinase domain (,37 kDa) and
a longer C-terminal fragment with the RIP homotypic interaction
motif (RHIM) and death domain (,39 kDa) [46]. Processing of
RIPK1 was highly inhibited in the presence of the caspase
inhibitor zVD (Fig. 3A).
To further study the molecular components involved in STS-
triggered necroptotic pathway under caspase-compromised con-
ditions we investigated the role of MLKL. Cells were treated with
various concentrations of NSA, an inhibitor of MLKL [14]. NSA
reduced the ratio of PI positive cells in a concentration-dependent
fashion independently of the way of cell death trigger (either
TRAIL or STS) under caspase-compromised condition (Fig. 3B).
Complete inhibition was observed at NSA concentration of
0.5 mM, the same concentration as reported by Sun et al. [14].
NSA at the applied concentration arrested both the TRAIL and
STS-triggered necrosis, confirmed by PI uptake measurements
(Fig. 3C) and also by Hoechst/PI double staining method (Fig. 3D).
Meanwhile NSA failed to reverse the STS-evoked DNA fragmen-
tation (Fig. S3A, S3B) or prevent secondary necrosis (Fig. 3SB).
These results confirmed the crucial role of RIPK1 and MLKL
in STS and TRAIL-induced necrosis under caspase-compromised
conditions. Therefore we can consider the observed necrosis in
U937 cells as necroptosis.
CA Inhibits both the TRAIL and STS-induced Necroptosis
in the Presence of a Caspase Inhibitor
Previously we found that CA-074-OMe (CA), an inhibitor of
cysteine cathepsins, rescued the caspase-independent necrotic
form of cell death of promyelocytic leukemia cells treated by STS
[34]. In this study we tested whether CA (10 mM) treatment might
promote the survival of U937 cells dying under necroptotic
conditions.
Interestingly CA almost completely hampered the TRAIL-
induced necroptotic cell death measured by plasma membrane
rupture (Fig. 4A). Moreover, CA was comprehensive inhibitor of
STS-triggered necroptosis too (Fig. 4B). In case of both inducers,
CA abolished the ratio of PI positive cells in a concentration-
dependent manner (Fig. S4A, S4B). IC50 amount was approxi-
mately at 5 mM in both cases (Fig. S4A, S4B). To further
characterize the effect of CA on the necroptotic pathway and to
compare to the inhibitory activities of Nec and GA, its action on
different cellular compartments were investigated. Time course
detection of mitochondrial membrane depolarization was carried
out by flow cytometric analysis of DiOC6(3) stained STS+zVD-
treated U937 cells. Our results confirmed that a continuous, time-
dependent reduction of mitochondrial membrane integrity hap-
pens in the cell population (Fig. 4C). While Nec prevented
partially the cells to loose their mitochondrial membrane potential
for STS-treatment, CA provided nearly complete protection under
caspase activity arrested conditions (Fig. 4C). Furthermore Nec
completely inhibited the appearance of AnnexinV and PI double
positive cell population after TRAIL and zVD co-treatment
(Fig. 4D). In case of STS treatment, the depletion was just partial
(Fig. 4D) in concordance with the earlier mentioned PI positivity
results (Fig 2D, 2E). Contrarily, the effect of CA treatment on the
reduction of phosphatidylserine (PS) translocation and plasma
membrane rupture was complete (Fig. 4D). Similarly, the
complete arrest of CA on plasma membrane rupture was detected
by PI uptake (Fig. 4A, 4B) and by Hoechst/PI double staining
technique for STS (Fig. 4E) or TRAIL (data not shown) treated
U937 cells in the presence of zVD. Moreover the loss of lysosomal
acidity induced either by STS (Fig. 4F, 4G) or TRAIL (Fig. S4C)
treatment under necroptosis inducing conditions was remarkably
withheld by CA pretreatment. Additionally CA could significantly
prevent the loss of mitochondrial membrane depolarization in
both cases of STS (Fig. 4C, 4H, 4I) and TRAIL (Fig. 4H)
treatment in the presence of the caspase inhibitor zVD.
Compared to the aforementioned effects of CA, Nec was only
partially effective inhibitor of all the measured cellular functions in
STS-triggered necroptosis (Fig. 4C, 4D, 4F, 4G, 4H, 4I). On the
other hand Nec completely diminished the TRAIL-induced
necroptosis (Fig. 4D, 4F, 4H, Fig. S4C, S4D). The observed
apoptotic parameters: the invariable percentage of the sub-G1 cell
population (Fig. S4E, S4F, S4G) and the presence of ladder type
DNA degradation observed in agarose gels (Fig. S4H) proved that
CA had no effect on caspase-dependent apoptosis or on the
ensuing secondary necrosis (Fig. 4A, 4B) in TRAIL or STS-
exposed cells. Moreover, the absence of proteolytic degradation of
RIPK1 also confirmed the avoidance of apoptosis (Fig. S4I).
From these data we surmised that CA, similarly to NSA is also
an effective inhibitor of the necroptotic pathway induced by STS
in the presence of caspase inhibitor. While Nec and GA withheld
only the early phase of STS-induced necroptosis in U937 cells.
PJ-34 does not Arrest Either the TRAIL or STS-induced
Necroptosis in the Presence of a Caspase Inhibitor
Participation of PARP-1 enzyme is well documented at several
levels of cell death processes [6]. Applying PARP inhibitor reduces
the rate of PARP activation and slows down the exhaustion of
nicotinamide adenine dinucleotide (NAD) and ATP pools,
therefore generally shifts the cell death process towards apoptosis
and prevents necrosis [15].
In our experimental system we tested the effect of PARP-1
enzyme inhibitor PJ-34 on the necroptotic cell death pathway.
Major differences in the necroptotic process were not observed in
the presence of the inhibitor. In STS or in TRAIL-treated and
caspase-inhibited U937 cells PJ-34 did not influence the changes
observed in mitochondrial transmembrane potentials (Fig. 5A, Fig.
S5A), in PI permeability of cells (Fig. 5B, 5C), in the acidity of
lysosomes (Fig. 5D, Fig. S5B) or in the PS distribution in the
plasma membrane (Fig. 5E, data not shown). Furthermore, neither
the caspase-dependent nor the caspase-independent STS or
Figure 2. STS induces primary necrosis in the presence of caspase inhibitor. (A-B) Nec (10 mM) and (C) GA (1 mM) significantly inhibited the
STS-triggered necroptosis. Cells were exposed to STS (1 mM) in the presence or absence of zVD (5 mM) for 12 hrs. Percentage of PI positive cells was
determined by flow cytometry (A, C). (n=4) and by Hoechst/PI double staining technique (B) (representative of n=2), (400x). Scale bar on the first
subfigure applies to all the figures in the panel. (D) Nec (10 mM) arrested the STS-induced (1 mM) necroptosis in the presence of zVD (5 mM) after
20 hrs incubation. The mitochondrial transmembrane potential and plasma membrane integrity is shown in representative dot plots of DiOC6(3) and
PI stained, unfixed cells. The values indicate the percentage of cells in the marked regions (n=13). (E-G) Nec (10 mM) (E, F) and GA (1 mM) (G) partially
inhibited the STS-triggered necroptosis. Cells were exposed to STS (1 mM) in the presence or absence of zVD (5 mM) for 20 hrs. Percentage of PI
positive cells was determined by flow cytometric analysis (E, G) (n=13 for Nec and n=4 for GA), and by Hoechst/PI double staining technique (F)
(n=2). Scale bar on the first subfigure applies to all the figures in the panel. Values are mean6SD. *, P,0.05, **, P,0.01 and ***, P,0.001 calculated
by Student’s t-probe.
doi:10.1371/journal.pone.0041945.g002
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the applied PARP-1 inhibitor (Fig. 5F, Fig. S5C).
At the same time the secondary necrotic cell death process was
postponed by PJ-34 in a concentration-dependent manner. This
effect was confirmed by the observed intact plasma membrane
integrity both under STS (Fig. 5B, 5G) and TRAIL-induced
(Fig. 5C) conditions where the enzyme activity of PARP-1 was
increased in the absence of the inhibitor (unpublished results). In
addition, the loss of lysosomal acidity was notably reduced by PJ-
34 during prolonged treatment of U937 cells with STS (Fig. 5D)
Figure 3. STS induces RIPK1 and MLKL-dependent necroptosis. (A) zVD hampered RIPK1 fragmentation triggered by STS for 12 hrs. Western
blot analysis was performed for the detection of RIPK1 protein level and presence of cleaved fragment due to caspase activity (representative of
n=2). (B) NSA reduced TRAIL and STS-induced necroptosis in a concentration-dependent manner after 20 hrs incubation time – representative
experiment. U937 ells were exposed to STS (1 mM) and TRAIL (50 ng/mL) and varying concentrations of NSA (0–2.5 mM) in the presence of zVD (5 mM)
for 20 hrs. Percentage of PI positive cells was determined. (C-D) NSA (0.5 mM) significantly hampered both the TRAIL and STS-triggered necroptosis.
(C) Relative percentage of PI positive cells was determined by FACS analysis (n=3). Values are mean6SD. *, P,0.05, **, P,0.01 and ***, P,0.001
calculated by Student’s t-probe. (D) Morphological signs of apoptosis and necrosis are shown in representative fluorescent microscopic images (400x)
of Hoechst/PI double stained U937 cells (n=2). Scale bar on the first subfigure applies to all the figures in the panel.
doi:10.1371/journal.pone.0041945.g003
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TRAIL treatment as well (Fig. S5B).
Contrary to the necrotic process, in cases of STS or TRAIL-
induced apoptosis PJ-34 showed only marginal effect on the cell
death process. The hallmarks of apoptosis including PS distribu-
tion (Fig. 5E, Fig. data not shown), loss of mitochondrial
transmembrane potential (Fig. 5A, Fig. S5A) and the DNA
fragmentation (Fig. 5F, Fig. S5C) were not influenced by PJ-34.
Note, that in Figure 5E most STS-treated cells are Annexin and PI
positive while in the presence of PJ-31 more than half of the cells
were not stained with PI indicated that PJ-34 prevented
postapoptotic membrane disruption.
These results indicate that PJ-34 could only delay the secondary
necrosis, but was unable to prevent the caspase-dependent
apoptosis. Our results show that the enzymatic activity of
PARP-1 directly or indirectly influences the process of secondary
necrosis but is dispensable in necroptosis at least in TRAIL and
STS-treated U937 cells.
Discussion
In this report we analyzed different aspects of cell death
modalities in TRAIL and STS-treated monocytic U937 cells by
using known inhibitors of the apoptotic, necrotic and necroptotic
processes. We have found that under caspase-compromised
conditions necroptosis can be triggered both by TRAIL and
STS, which compounds are classical inducers of the extrinsic and
intrinsic apoptotic pathways respectively. Necroptosis could be
arrested by the MLKL inhibitor NSA, by the RIPK1 inhibitor
Nec, by the HSP90 inhibitor GA and by the cathepsin B inhibitor
CA. On the other hand PJ-34, a PARP-1 inhibitor did not affect
the necroptotic pathway, but effectively arrested the progress of
secondary necrosis ensued the caspase-mediated apoptosis, at least
in U937 cell line.
First, we built up a model system to study the classical death
ligand-triggered necroptosis. We selected TRAIL cytokine as
inducer of cell death which compound is a promising anticancer
agent. Although, it was investigated as a potent and selective
apoptosis inducing agent in malignant cells [36], its effect on the
necroptotic process was not known in detail. In U937 human
monocytic cell line TRAIL induced apoptotic cell death with a
moderate intensity, characterized by caspase activation, PARP-1
cleavage and ladder type DNA degradation. After extended
periods of TRAIL treatment, apoptosis was followed by a
secondary necrotic process. Applying zVD pan-caspase inhibitor
together with TRAIL, turned the apoptotic process into a
necroptotic cell death form that was arrested by Nec, and none
of the signs of apoptosis or that of secondary necrosis were
observed even after 20 hours of treatment. These results are in
concordance with recent publications [13,39]. After confirming
that U937 cells can show apoptotic, necroptotic or secondary
necrotic phenotypes upon TRAIL treatment, we started to study
the effect of inhibitors influencing certain segments of cell death
pathways.
We tested the effect of GA, an inhibitor of the ATP-ase activity
of the chaperone protein HSP90. U937 cells were pre-treated with
GA (4 hrs) or Nec (1 hr) both in the absence and presence of zVD
before TRAIL administration, and the changes of biochemical
events were recorded. Nec or GA prevented the rupture of plasma
membrane, due to the inhibition of RIPK1 kinase activity by Nec
and partial downregulation of RIPK1 protein level by GA in line
with the literature [39,47]. Nec did not affect the extent of
TRAIL-induced apoptosis or secondary necrosis in the presence of
caspase activation. However, GA administration increased the
ratio of apoptotic U937 cells possibly by decreasing the RIPK1-
dependent NFkB activation [43]. Previously RIPK1 was described
to serve as an adapter surface having critical role in the activation
of apoptotic and in NFkB pathways, where its kinase activity is
dispensable [48–50]. Contrarily, kinase activities of RIPK1 and
RIPK3 are crucial for necroptosis [13,20,21].
Previously we published that STS induced necrosis in U937
cells where caspase activities were halted by a broad spectrum
caspase inhibitor [30]. Detection of early plasma membrane
rupture, morphological characteristics and the absence of caspase
activities were considered as important signs of necrotic cell death.
In the current study we asked if the STS-induced cell death
measured in the absence of caspase activities can be considered as
necroptosis.
We detected that the STS-induced, caspase activity-indepen-
dent necrotic-like cell death was also withheld by Nec and GA pre-
treatments. This inhibitory action was almost complete after 12
hours and was partial but still significant if the incubation time was
longer (20 hrs). Further supporting information is available in Text
S1. The reason of the incomplete inhibition of Nec or GA
observed after extended periods of treatments with STS and zVD
might be connected to alternatively activated cell death pathways
(e.g. autophagy). Further supporting information is available in
Text S2.
RIPK1 was processed in the STS-induced apoptosis that was
dominantly inhibited by the caspase inhibitor zVD. The size of the
fragment is in accordance with the caspase-8-mediated cleavage of
RIPK1 [51]. As the STS-triggered necroptosis could proceed only
in the presence of caspase inhibition, the absence of RIPK1
degradation also supports its role in the STS-evoked necroptosis.
Additional supporting information is available in Text S3. To
further investigate the possible members of the STS-provoked
necroptosis we tested the involvement of MLKL in the process.
Our results show that both the TRAIL and the STS-induced
necroptosis were prevented by NSA. This observation suggests
that not only RIPK1 but MLKL are also involved in the STS-
triggered necroptotic pathway. As Nec provides only a partial
Figure 4. CA inhibits either the TRAIL or STS-induced necroptosis in presence of caspase inhibitor. U937 cells were treated either with
STS (1 mM) or with TRAIL (50 ng/mL) in the presence or absence of zVD (5 mM) for 20 hrs. Nec (10 mM) or CA (10 mM) were added 1 hr before cell
death was induced. (A-B) CA (10 mM) considerably inhibited the (A) TRAIL (n=4) or (B) STS-triggered necroptosis (n=3). Percentage of PI positive cells
was determined. (C) Time course analysis of cells with depolarized mitochondria is shown after DiOC6(3) staining of, unfixed cells for STS treatment
combined with the indicated inhibitors (n=2). Values are mean6SD. *, P,0.05, **, P,0.01 and ***, P,0.001 calculated by Student’s t-probe. (D) PS
distribution in the plasma membrane is shown in representative dot plots of Annexin V-FITC and PI stained, unfixed cells analyzed by flow cytometry.
The values indicate the percentage of cells in the marked regions (n=2). (E) Morphological signs of apoptosis and necrosis are shown in
representative fluorescent microscopic images (400x) of Hoechst/PI double stained U937 cells (n=2). Scale bar on the first subfigure applies to all the
figures in the panel. (F) Distribution of cells with various volumes of acidic compartments (endo-lysosomes) is shown in representative overlay
histograms of AO stained cells analyzed by flow cytometry. (G) Column diagram of percentage of cells with high AO red fluorescence intensity (n=2).
(H) Distribution of cells with various mitochondrial transmembrane potential is shown in representative overlay histograms of DiOC6(3) stained cells
analyzed by flow cytometry. (I) Column diagram of percentage of cells with high DiOC6(3) fluorescence intensity (n=3). Values are mean6SD. *,
P,0.05, **, P,0.01 and ***, P,0.001 calculated by Student’s t-probe.
doi:10.1371/journal.pone.0041945.g004
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hypothesis that STS acts through two parallel pathways which are
equally dependent on MLKL.
How STS induces necroptosis is rather enigmatic. Death
receptor-independent assembly of Ripoptosome is a recently
proposed model [24]. This process is controlled by endogenous
inhibitors of apoptosis proteins (cIAPs) and the X-linked inhibitor
Figure 5. PJ3-4 does not arrest either the TRAIL or STS-induced necroptosis in presence of caspase inhibitor. U937 cells were treated
either with STS (1 mM) or with TRAIL (50 ng/mL) in the presence or absence of zVD (5 mM) for 20 hrs. PJ-34 (1 mM) was added 1 hr before cell death
was induced. (A) Column diagram of percentage of cells with high DiOC6(3) fluorescence intensity (n=3). (B-C) PJ-34 (1 mM) considerably inhibited
the (B) STS (n=8) or (C) TRAIL-triggered (n=8) secondary necrosis but not the necroptosis. Percentage of PI positive cells was determined. Values are
mean6SD. *, P,0.05, **, P,0.01 and ***, P,0.001 calculated by Student’s t-probe. (D) Column diagram of percentage of cells with high AO
fluorescence intensity (n=2). (E) Dot plot distribution of cells stained with Annexin V-FITC and PI analyzed by flow cytometry. The values indicate the
percentage of cells in the marked regions (representative of n=2). (F) Representative histograms of distribution of PI stained, ethanol-fixed (sub-G1)
cells were analyzed by flow cytometry (n=8). The numbers indicate the percentage of cells in the marked regions. (G) PJ-34 concentration
dependently reduced the proportion of PI positive cells for STS treatment for 20 hrs – representative experiment.
doi:10.1371/journal.pone.0041945.g005
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components of Ripoptosome [25]. Tenev et al. found that during
etoposide-induced genotoxic stress the levels of cIAPs and XIAP
decreased causing the spontaneous formation of the Ripoptososme
[25]. Conceivably during STS-induced necroptosis the cIAP and
XIAP level also decrease and therefore the formation of
Ripoptosome can occur. This notion is supported by former
publications revealing that STS decreases the level of XIAP in
leukemia cells [52] and in MCF-7 cells [53].
Previously, cathepsin B, a ubiquitous lysosomal cysteine
protease was shown to be a component of TNFa-induced cell
death pathway [54]. In the absence of caspase activity cathepsins
were shown to process cellular proteins leading either to apoptosis
[55] or necrosis [56]. We previously discussed that CA-074-OMe,
the methylated variant of a highly specific inhibitor of cathepsin B
[57] abrogated the necrotic cell in caspase-inhibited leukemia cells,
independently from its inhibitory effect on cathepsin B [34]. In this
study we demonstrated that CA stabilized the acidic pH of the
lysosomal compartment, prevented the membrane potential loss of
mitochondria and finally the rupture of plasma membrane. This
indicates that the target of CA is functionally located upstream of
the lysosomal breakdown and the mitochondrial depolarization
[34]. Van den Berghe and his colleagues recently found that CA
significantly blocked TNFa-induced necroptosis [58]. Our results
with TRAIL and STS demonstrated that CA completely
abrogated necroptosis at 10 mM concentration in the caspase-
inhibited U937 cells. However, this CA concentration was higher
with orders compared to concentration required for inhibition of
cathepsin B protease activity [34,59]. Thus the effective target of
CA in necroptosis remains to be determined.
Participation of PARP and the effect of PARP inhibitor on the
prevention or during the induction of cell death are very much cell
type dependent. Inhibition of PARP activity might prevent cell
death via preventing the exhaustion of a cell’s ATP and NAD
pools or by inhibiting the transfer of AIF from mitochondria to cell
nuclei. In U937 cells, PARP inhibitor did not influence either the
apoptotic or the necroptotic cell death pathways induced either by
TRAIL or STS, but were able to postpone the secondary necrotic
process. Further supporting information is available in Text S4.
In this publication we proved that TRAIL, a death receptor
ligand cytokine, which generally induces apoptotic cell death
through the extrinsic pathway, under caspase compromised
conditions trigger necroptosis in U937 cells. We have also shown
that STS, a kinase inhibitor compound which generally induces
apoptosis through the intrinsic pathway can also induce necrop-
tosis under caspase-deprived conditions. Our results might have
clinical relevance in the fight against tumors. Treatment with
proper inductors can activate the necroptotic cell death form in
apoptosis resistant tumor cells. Moreover applying PARP inhib-
itors to delay secondary necrosis might control the tumor lysis
syndrome, where the intracellular content spilling out from the
abruptly dying large number of cells poisoning the whole body.
Furthermore we have shown that CA inhibits the necroptotic cell
death. This result point out that the currently unknown target of
CA can pharmacologically be important in necroptotic cell death.
The flow chart shown in Figure 6 summarizes the hypothetic
places of actions, where the drugs were used in the current study to
inhibit the STS or TRAIL-induced cell death pathways in U937
cells.
We hope that the presented results will contribute to the better
understanding of the molecular background of necroptosis and
propagate research on CA to find novel drug candidates against
necroptotic cell death.
Materials and Methods
Materials
Staurosporine, PARP inhibitor (PJ-34), geldanamycin (GA),
RNase A, propidium iodide (PI), DiOC6(3), acridine orange (AO),
Hoechst 33258 and cell culture products were purchased from
Sigma-Aldrich (St. Louis, MO, USA). hr-TRAIL (114-281 aa) was
prepared as described earlier [60]. z-Val-DL-Asp-fluoromethylk-
etone (zVD) and CA-074-OMe (CA) were purchased from
Bachem (Bubendorf, Switzerland). Necrostatin-1 (Nec) was
obtained from Calbiochem (Darmstadt, Germany). Antibody
against PARP-1 was ordered from Cell Signaling Technology,
(Danvers, MA), (#9542), against RIPK1 from Becton Dickinson
(Budapest, Hungary), (610458) and against GAPDH from Santa
Cruz (Heidelberg, Germany, (D-6) sc-166545). Necrosulfonamide
(NSA) was a kindly gift of Professor Xiaodong Wang (Beijing,
China).
Cell Culture
U937 promonocytic cell line was purchased from ATCC. Cells
were cultured in RPMI 1640 supplemented with 10% heat
inactivated fetal bovine serum, 2 mM L-glutamine and 100 mg/
mL penicillin and 100 units/ml streptomycin at 37uCi na5 %
CO2 containing, humidified incubator. Cells were regularly tested
for the presence of certain human CD antigens: CD45 (+); CD33
(+); CD13 (+); CD34 (2); CD14 (2); CD4 (2). Antibodies directly
labeled with fluorochrome were purchased from Becton-Dickinson
(Franklin Lakes, NJ USA). For treatments, cells were distributed
into 48-well suspension plate (Greiner), 0.5 mL into each well at a
cell density of 3610
5 cells/mL or 5610
5 cells/mL, 60 minutes
before drug treatment. Then zVD (10 mM) was added with or
without together other drugs as described above started 1 hr (Nec,
CA, NSA, PJ) or 4 hrs (GA) before STS (1 mM) or TRAIL (50 ng/
mL) addition. Duration of drug treatments varied between 4–24
hours.
Detection of the Cell Death-associated Functional
changes by Flow Cytometry
Data collection was carried out using FACScan flow cytometer
(Becton Dickinson) see hereinafter, and analysis of the results was
performed by WINLIST software (VERITY Software House,
Figure 6. Schematic diagram about the action of inhibitors on
TRAIL and STS- induced cell death pathways. Both TRAIL and STS
triggered necroptosis in caspase depleted U937 cells upon prolonged
incubation time. RIPK1 inhibitors Nec and GA could completely inhibit
the TRAIL-evoked necroptosis, but had partial inhibitory potential to the
STS-provoked process. Contrarily CA and NSA abolished both the TRAIL
and STS-induced necroptosis. In absence of caspase inhibitor TRAIL and
STS induced apoptosis which is followed by secondary necrosis. PJ-34
delayed the necrotic plasma membrane disruption during secondary
necrosis, but failed to inhibit necroptosis.
doi:10.1371/journal.pone.0041945.g006
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to fluorescence channels: FL1:530/30 nm; FL2:585/42 nm;
FL3:650LP. Analysis was performed on the amplitude (height,
H) of the fluorescence signal in log scale. A doublet discrimination
panel was set on FL2 channel for the detection of FL2A (area) and
FL2W (width) of the fluorescence signals are shown in linear scale.
Assay of PI Uptake of Native Cells Representing the
Damage of Plasma Membrane
An increase of permeability of the cell membrane is a
characteristic signal for the early phase of necrosis and can be
detected using flow cytometry. Treated or non-treated cells were
stained directly by adding 0.5 mL PBS containing 5 mM glucose
and 10 mg/mL PI to each well, and incubated for a further 15
minutes at 37uC in the CO2 incubator. Necrotic (PI positive) cells
usually lost light scatter intensity therefore they mixed up with
debris in the [FSC, SSC] two-dimensional parameter diagram.
For gating necrotic cells out of debris we applied [FSC, FL3H]
diagram where necrotic cells contained high amount of DNA
could be separated from debris contained low amount of DNA.
Gated cells were analyzed on FL2H log scale histograms where the
population with low fluorescence intensity represents the PI
negative population, while the population displaying high fluores-
cence represents the membrane ruptured PI positive cells. Data
were presented as percentage of cells. In certain experiments,
samples were co-labeled with DiOC6(3) or Annexin V-FITC
together with PI labeling and used for analysis PI uptake.
Characterization of Phosphatidylserine Distribution in the
Plasma Membrane by Flow Cytometry Analysis of
Annexin V-FITC and PI Double-labeled Cells
The assay was performed according to the suggestions of the
vendor (Alexis Biochemicals, Lausen, Switzerland). Briefly, cells in
suspension cultures were stained with an equal volume of PBS
containing 5 mM glucose and 10 mg/mL PI in the wells and
incubated further for 10 minutes at 37uC. After centrifugation
(3006g/2 min), cells were suspended in 400 mL binding buffer
(10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2) and stained
with 5 mL AnnexinV-FITC for 10 minutes in dark. Thereafter an
additional 400 mL of binding buffer, containing 1 mg/mL PI was
add to the samples and measured immediately. The [FSC, FL3H]
diagram was applied for gating and the gated cells were analyzed
in [FL1H, FL2H] log scale two dimensional diagram. Auto-
fluorescence of the cells was positioned in first decade, and
compensation for FITC fluorescence in the FL2 channel was
applied. Data were presented as percentage of cells in the marked
regions of the diagram.
Changes of Mitochondrial Transmembrane Potential
were Characterized by the DiOC6(3) Uptake Method
Samples were prepared for the measurements according to
Darzynkiewicz and Bender [61], with minor modifications. Pre-
treated cells were stained with an equal volume of PBS containing
5 mM glucose, 10 nM DiOC6(3) and 10 mg/mL PI directly in the
wells and incubated further for 15 minutes at 37uC and analyzed
without further washing steps by FACS. Fluorescent signals of the
cells were gated in [FSC, FL3H] diagram, analyzed on FL1H log
scale histograms and the data were presented as fluorescence
intensity of the whole gated cell population. High DY, but PI
negative cells were considered as functioning mitochondria–
containing, surviving population of cells.
Functioning Lysosomal Compartments are Characterized
by the Red Fluorescence of Acridine Orange in the Acidic
Environment of Lysosomes
Treated cells were stained with an equal volume of PBS
containing 5 mM glucose and 5 mg/mL AO directly in the wells
and incubated for a further 15 minutes at 37uC. The pelleted cells
(3006g/2 minutes) were resuspended in 1 mL of 5 mM glucose
containing PBS and analyzed by FACS immediately. Cells were
gated in [FL1H, FL3H] diagram for discriminating cells with high
DNA content from debris with low amount of DNA. The gated
populations were analyzed on FL3H log scale histograms and the
data were presented as fluorescence intensity of the whole
population.
Determination of Oligonucleosomal DNA Fragmentation
by the Measurement of Sub-G1 Population of Cells
Apoptosis was characterized by measuring the sub-G1 pool of
cells as an indication of DNA fragmentation. Samples were
prepared according to Gong et al. [62]. Briefly, treated cells were
pelleted (3006g/2 min) and the cells were suspended in 1 mL
70% ethanol (220uC), and were fixed at room temperature for a
half hour. The ethanol-fixed cells were sedimented again and their
broken, oligonucleosomal sized DNA content were extracted by
treating the cells with 750 mL of extraction buffer containing
200 mM Na2HPO4/citric acid (pH=7.8) buffer containing
10 mg/mL RNAse A, for 15 minutes. The DNA remaining inside
the permeabilized cells were stained with 5 mg/mL of PI for at
least 10 minutes before FACS analysis. Cells were gated in (FSC,
FL2H) diagram for discriminating debris and analyzed on FL2H
log scale histogram as percentage of cells in the marked, sub-G1
region.
Agarose Gel Electrophoresis
DNA fragmentation was analyzed as described earlier [63].
Briefly, U937 cells (one million cells per sample) were treated for
20 hrs as indicated at the legends of Figure S2H and Figure S4H.
Then cells were collected, washed with PBS and resuspended in
300 ml of a solution, containing 10 mM Tris-HCl, pH 7.5, 1 mM
EDTA, 0.15 M NaCl, 1% SDS supplemented with 0.2 mg/ml of
proteinase K and incubated overnight at 37
oC. Samples were
phenol-chloroform extracted once and their DNA content were
precipitated in ethanol, pelleted and redissolved in 50 mlo fT E
buffer containing 0.2 mg/mL DNAse free RNAse and incubated
for an hour at 37
oC. DNA was electrophoresed in 1.5% agarose
gel in TBA buffer, stained with ethidium bromide and DNA was
detected under UV light.
Light Microscopic Studies
Cytospin preparations (10
5 cells) were fixed in methanol, stained
with hematoxylin-eosin, were dehydrated with subsequent extrac-
tions with ethanol, acetone and xilol. The morphological changes
of apoptosis were studied by light microscopy at 400x magnifica-
tion. Cells were categorized according to the recommendations of
Kroemer et al. [64] as follows: stage I apoptotic cells have
moderately condensed nuclei (including smooth nuclei too); stage
II apoptotic cells have full blown nuclear condensation (pyknosis)
and formation of nuclear apoptotic bodies (karyorrhexis). Necrosis
was characterized by cell swelling and blurred plasma membrane.
Ghost cells with washed out cytoplasmic contents were identified
as being in the late necrotic stage.
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Treated U937 cells were pelleted (3006g/3 min) and were
stained with 2 mM Hoechst dye (332581) in 1 mL 5 mM glucose
containing PBS to distinguish between apoptotic and necrotic
cells. After an incubation for 30 minutes at 37uC, cells were
pelleted (3006g/3 minutes) again and resuspended in 10 mLo f
5 mM glucose and 10 mM PI containing PBS and were
immediately photographed under a fluorescence microscope
(Nikon Eclipse E 400, Japan) at 400x magnification using a
SPOT Jr Camera. Excitation wavelength of 330–380 nm was
applied for Hoechst dye and 450–490 nm for PI. Apoptotic cells
were identified on the basis of morphologic changes in their
nuclear assembly by observing chromatin condensation and
fragment staining by the Hoechst dye. Secondary necrotic cell
were identified based on positive staining with PI and apoptotic
nuclear morphology with Hoechst dye. In each case at least four
microscopic fields were photographed randomly. The experiments
were repeated at least twice.
Western Blot Representation of PARP-1 and RIPK1
Cleavage
Western blot analysis of the proteolytic degradation of PARP-1
and RIPK1 was carried as published [65]. U937 cells were treated
as indicated at the legends of Figure 1B, Figure 3A, and Figure
S4I. After treatment cells were collected, washed with PBS and
resuspended in 50 ml of Laemmli sample buffer. After boiling the
samples their 20 ml aliquots were electrophoresed in a 10% SDS-
PAGE gel and blotted onto nitrocellulose. After blocking
membranes with 3% milk in PBS overnight, specific antibodies
against PARP-1 (#9542, Cell Signaling Technology) or RIPK-1
(BD 610458) were added, incubated for 3 hours and membranes
were washed exhaustively with 1% milk containing PBS (25 ml of
each washing step) and with PBS twice. Proteins were visualized
by ECL. After immuno-detection of RIPK-1 protein levels in cells,
blots were stripped and reprobed with an anti GAPDH antibody
(Santa Cruz, (D-6) sc-166545). The intensities of GAPDH bands
served as loading controls.
DEVD-ase Activity Assay
Aliquots of cells (5610
5 cells/mL) incubated for different
durations of time with drugs were withdrawn centrifuged and
washed with PBS twice (3006g/2 minutes) and finally were
suspended in 100 ml of caspase buffer (50 mM HEPES (pH=7.4),
100 mM NaCl, 0.1% (w/v) CHAPS, 10% (w/v) sucrose and
10 mM DTT. After transferring samples into wells of 96-well
plates, Triton X-100 (final concentration of 0.2%) were added,
and cell lysis was completed by repeated up and down pipetting of
the cells. Caspase substrate z-DEVD-AMC (20 mM) was admixed,
and fluorescence intensities of the liberated AMC were recorded
for 15 minutes in Fluoroskan Ascent fluorescence plate reader
(Thermo Fisher Scientific, Waltman MA, USA). Excitation
wavelength was 380 nm and emission is measured at 445 nm.
Protease activity was expressed as the slope of the AMC
fluorescence curves.
Statistics
Statistical analysis and significance of differences in comparable
values were calculated by applying Student’s t-probe (two tailed,
two sample unequal variance) and the indicated significance of
differences in the graphs are: P,0.05 (*); P,0.01 (**); P,0.001
(***).
Supporting Information
Figure S1 TRAIL induces necrotic type DNA degrada-
tion in the presence of caspase inhibitor. Representative
histograms of PI stained, ethanol-fixed U937 cells, detected by
flow cytometry (sub-G1 technique). Inserted values indicate the
percentage of cells in the marked regions. U937 cells were exposed
to TRAIL (50 ng/mL) in the presence or absence of zVD (5 mM)
and Nec (10 mM) or GA (1 mM) for 20 hrs (n=3).
(TIF)
Figure S2 STS induces necrotic type DNA degradation
in the presence of caspase inhibitor. (A) Nec reduced the
STS-induced necroptosis in a concentration-dependent manner
after 8 hrs incubation time – representative experiment. Cells were
exposed to STS (1 mM) and varying concentrations of Nec (0–
50 mM) in the presence of zVD (5 mM) for 8 hrs. Percentage of PI
positive cells was determined. (B-F) STS induced DNA fragmen-
tation. U937 cells were treated with STS (1 mM) in the presence of
zVD (5 mM) for 12 hrs or 20 hrs. Cells were pre-treated with Nec
(10 mM, 1 hr) or GA (1 mM, 4 hrs). (B, D) Representative
fluorescent microscopic images (400x) of Hoechst/PI double
stained U937 cells (n=2). Scale bar on the first subfigure applies
to all the figures in the panel. (C, E, F) Representative histograms
of PI stained, ethanol-fixed cells detected by flow cytometry (sub-
G1 technique) (n=3 for 8 hrs with Nec, n=13 for 20 hrs with
Nec and n=4 for 20 hrs with GA treatments). Inserted values
indicate the percentage of cells in the marked regions. (G) STS-
induced caspase (DEVDase) activity in U937 cells. The ordinate
shows the slope of the measured DEVDase activity curves of a
representative experiment carried out in triplicates. (H) STS-
induced DNA fragmentation. Agarose gel electrophoresis was
performed to detect the DNA ladder formation. Cells were treated
as indicated for 20 hrs (representative of n=2).
(TIF)
Figure S3 TRAIL and STS induce MLKL-independent
DNA fragmentation and secondary necrosis. (A) Repre-
sentative histograms of PI stained, ethanol-fixed U937 cells
detected by flow cytometry (sub-G1 technique). Inserted values
indicate the percentage of cells in the marked regions. U937 cell
were exposed to TRAIL (50 ng/mL) or STS (1 mM) and NSA
(0.5 mM) for 20 hrs (n=3). (B) Morphological signs of apoptosis
and necrosis are shown in representative fluorescent microscopic
images (400x) of Hoechst/PI double stained U937 cells (repre-
sentative of n=2). Scale bar on the first subfigure applies to all the
figures in the panel.
(TIF)
Figure S4 CA inhibits both the TRAIL and STS-induced
necroptosis in the presence of caspase inhibitor. U937
cells were treated either with STS (1 mM) or with TRAIL (50 ng/
mL) in the presence or absence of zVD (5 mM) for 20 hrs. Nec
(10 mM) or CA (10 mM or as indicated) were added 1 hr before
cell death was induced. (A-B) CA reduced the ratio of PI positive
cells for STS+zVD or TRAIL+zVD treatment for 20 hrs in a
concentration-dependent manner, representative experiments. (C)
Column diagram of percentage of cells with high AO fluorescence
intensity (n=2). (D) Column diagram of percentage of cells with
high DiOC6(3) fuorescence intensity (n=4). (E-F) Representative
histograms of PI stained, ethanol-fixed U937cells detected by flow
cytometry (sub-G1 technique). The numbers indicate the percent-
age of cells in the marked regions (n=3 for STS and n=4 for
TRAIL). Values are mean6SD. *, P,0.05, **, P,0.01 and ***,
P,0.001 calculated by Student’s t-probe. (G-H) STS-induced
DNA fragmentation and condensation. (G) Hoechst/PI double
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with samples treated as indicated for 20 hrs (representative of
n=2). Scale bar on the first subfigure applies to all the figures in
the panel. (I) zVD treatment prevents RIPK1 fragmentation
triggered by STS. Western blot analysis was performed for the
detection of RIPK1 protein level and presence of cleaved fragment
due to caspase activity (representative of n=2).
(TIF)
Figure S5 PJ-34 does not arrest the TRAIL-induced
necroptosis in the presence of caspase inhibitor. U937
cells were treated with TRAIL (50 ng/mL) in the presence or
absence of zVD (5 mM) for 20 hrs. PJ-34 (1 mM) was added 1 hr
before cell death induction. (A) Column diagram of percentage of
cells with high DiOC6(3) fluorescence intensity (n=4). (B) Column
diagram of percentage of cells with high AO red fluorescence
intensity (n=2). (C) Representative histograms of PI stained,
ethanol-fixed cells detected by flow cytometry (sub-G1 technique).
The numbers indicate the percentage of cells in the marked
regions (n=8).
(TIF)
Text S1 GA is more potent inhibitor than Nec during
STS-provoked necroptosis.
(PDF)
Text S2 Autophagy may play role in necroptosis.
(PDF)
Text S3 Nec can inhibit necrosis in a RIPK1-indepen-
dent manner.
(PDF)
Text S4 PARP-2 might be involved in the necroptotic
signaling pathway.
(PDF)
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